Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Apalutamide in Patients with High Burden of Metastatic Hormone-sensitive Prostate Cancer : A Subgroup Analysis of TITAN

Rodriguez-Vida, Alejo ; Borque, Angel ; Lopez-Campos, Fernando ; Soto, Alvaro Juarez ; Garcillan, Beatriz ; Vidal, Cristian ; Lencart, Joana ; Bhaumik, Amitabha ; Mundle, Suneel D. and Sanden, Suzy Van , et al. (2025) In European Urology Oncology 8(5). p.1311-1320
Abstract

BACKGROUND AND OBJECTIVE: A post hoc analysis of TITAN evaluated the clinical benefit of apalutamide plus androgen-deprivation therapy (ADT) versus ADT alone in metastatic hormone-sensitive prostate cancer (mHSPC) with high disease burden. METHODS: Patients were assessed in subgroups of those with four to fewer than ten, ten to <20, or ≥20 bone metastases; with lung but not liver metastases; and with no/mild or moderate/severe pain at baseline. Prostate-specific antigen (PSA) response, overall survival (OS), other endpoints, and safety were assessed using descriptive statistics, Kaplan-Meier method, and Cox proportional hazard model. KEY FINDINGS AND LIMITATIONS: Higher proportions of patients receiving apalutamide than those... (More)

BACKGROUND AND OBJECTIVE: A post hoc analysis of TITAN evaluated the clinical benefit of apalutamide plus androgen-deprivation therapy (ADT) versus ADT alone in metastatic hormone-sensitive prostate cancer (mHSPC) with high disease burden. METHODS: Patients were assessed in subgroups of those with four to fewer than ten, ten to <20, or ≥20 bone metastases; with lung but not liver metastases; and with no/mild or moderate/severe pain at baseline. Prostate-specific antigen (PSA) response, overall survival (OS), other endpoints, and safety were assessed using descriptive statistics, Kaplan-Meier method, and Cox proportional hazard model. KEY FINDINGS AND LIMITATIONS: Higher proportions of patients receiving apalutamide than those receiving placebo achieved a deep PSA response of ≤0.2 ng/ml at 3, 6, and 12 mo of treatment initiation regardless of the disease burden. OS benefit favored apalutamide plus ADT versus ADT alone in all bone metastasis subgroups: four to fewer than ten (hazard ratio [HR]: 0.68 [95% confidence interval 0.44-1.03]; p = 0.07), ten to <20 (0.61 [0.37-1.00]; p = 0.048), or ≥20 (0.53 [0.39-0.72]; p < 0.001) bone metastases. Addition of apalutamide to ADT was beneficial across other endpoints and in patients with lung but no liver metastases and regardless of pain at baseline. No new safety signals were observed across subgroups. CONCLUSIONS AND CLINICAL IMPLICATIONS: These findings provide strong evidence for early intensification with apalutamide plus ADT in patients with mHSPC regardless of the disease burden.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
High disease burden, Metastatic castration-sensitive prostate cancer, Metastatic hormone-sensitive prostate cancer, Oligometastatic, Pain, Polymetastatic
in
European Urology Oncology
volume
8
issue
5
pages
10 pages
publisher
Elsevier
external identifiers
  • scopus:105023440471
  • pmid:41027802
ISSN
2588-9311
DOI
10.1016/j.euo.2025.07.002
language
English
LU publication?
yes
id
44f6ca37-d157-47a1-adfb-9159a5650263
date added to LUP
2026-01-30 16:15:56
date last changed
2026-01-30 16:16:15
@article{44f6ca37-d157-47a1-adfb-9159a5650263,
  abstract     = {{<p>BACKGROUND AND OBJECTIVE: A post hoc analysis of TITAN evaluated the clinical benefit of apalutamide plus androgen-deprivation therapy (ADT) versus ADT alone in metastatic hormone-sensitive prostate cancer (mHSPC) with high disease burden. METHODS: Patients were assessed in subgroups of those with four to fewer than ten, ten to &lt;20, or ≥20 bone metastases; with lung but not liver metastases; and with no/mild or moderate/severe pain at baseline. Prostate-specific antigen (PSA) response, overall survival (OS), other endpoints, and safety were assessed using descriptive statistics, Kaplan-Meier method, and Cox proportional hazard model. KEY FINDINGS AND LIMITATIONS: Higher proportions of patients receiving apalutamide than those receiving placebo achieved a deep PSA response of ≤0.2 ng/ml at 3, 6, and 12 mo of treatment initiation regardless of the disease burden. OS benefit favored apalutamide plus ADT versus ADT alone in all bone metastasis subgroups: four to fewer than ten (hazard ratio [HR]: 0.68 [95% confidence interval 0.44-1.03]; p = 0.07), ten to &lt;20 (0.61 [0.37-1.00]; p = 0.048), or ≥20 (0.53 [0.39-0.72]; p &lt; 0.001) bone metastases. Addition of apalutamide to ADT was beneficial across other endpoints and in patients with lung but no liver metastases and regardless of pain at baseline. No new safety signals were observed across subgroups. CONCLUSIONS AND CLINICAL IMPLICATIONS: These findings provide strong evidence for early intensification with apalutamide plus ADT in patients with mHSPC regardless of the disease burden.</p>}},
  author       = {{Rodriguez-Vida, Alejo and Borque, Angel and Lopez-Campos, Fernando and Soto, Alvaro Juarez and Garcillan, Beatriz and Vidal, Cristian and Lencart, Joana and Bhaumik, Amitabha and Mundle, Suneel D. and Sanden, Suzy Van and Chi, Kim N. and Bjartell, Anders and Agarwal, Neeraj and Merseburger, Axel S.}},
  issn         = {{2588-9311}},
  keywords     = {{High disease burden; Metastatic castration-sensitive prostate cancer; Metastatic hormone-sensitive prostate cancer; Oligometastatic; Pain; Polymetastatic}},
  language     = {{eng}},
  number       = {{5}},
  pages        = {{1311--1320}},
  publisher    = {{Elsevier}},
  series       = {{European Urology Oncology}},
  title        = {{Apalutamide in Patients with High Burden of Metastatic Hormone-sensitive Prostate Cancer : A Subgroup Analysis of TITAN}},
  url          = {{http://dx.doi.org/10.1016/j.euo.2025.07.002}},
  doi          = {{10.1016/j.euo.2025.07.002}},
  volume       = {{8}},
  year         = {{2025}},
}